- Email: [email protected]
Genetic Risk and Its Implications for Cancer Surveillance
Annals of Oncology 25 (Supplement 4): iv11, 2014 doi:10.1093/annonc/mdu295.3
special symposium: germline genetics: important issues for oncologists 26IN
R. Eeles The Institute of Cancer Research, London, UK
abstracts
There is evidence for germline genetic variation predisposing to increased cancer risk. The data suggest that there are common risk variants each conferring a slightly increased risk (but multiplicatively these can give rise to substantial absolute risks in a proportion of individuals), and rarer higher risk variants which predispose to cancer risk, particularly to the common cancers, breast, colon, ovarian and prostate cancer.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv11/2240789 by guest on 26 October 2019
GENETIC RISK AND ITS IMPLICATIONS FOR CANCER SURVEILLANCE
This presentation will cover the spectrum of genetic predisposition to cancer and the implications for risk stratification in populations and individuals. These data will then be applied to clinical translational applications to targeted cancer surveillance. For some common cancers such as breast cancer and colon cancer, rarer genetic germline variants associated with high risks of the relevant cancer are already determining the use of targeted intensive screening programmes. In other common cancers, such as prostate cancer, the application of genetic risk profiling is still in the research arena but uses standard methods of screening which would be applied to the general population if the risk/benefit ratio of screening were favourable. Finally, some cancer syndromes are still subject to more experimental methods of screening such as whole body MRI scanning in individuals with germline TP53 mutations (the SIGNIFY study). In summary, genetic variation is starting to be used to undertake targeted screening and the application of genetic profiling in populations and individuals to targeted screening will be discussed. Disclosure: Prof Eeles has received educational grants from Illumina, Tepnel (now GenProbe), Vista Diagnostics and Janssen Pharmaceuticals and honoraria from Succinct Communications.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
special symposium: germline genetics: important issues for oncologists 26IN
R. Eeles The Institute of Cancer Research, London, UK
abstracts
There is evidence for germline genetic variation predisposing to increased cancer risk. The data suggest that there are common risk variants each conferring a slightly increased risk (but multiplicatively these can give rise to substantial absolute risks in a proportion of individuals), and rarer higher risk variants which predispose to cancer risk, particularly to the common cancers, breast, colon, ovarian and prostate cancer.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv11/2240789 by guest on 26 October 2019
GENETIC RISK AND ITS IMPLICATIONS FOR CANCER SURVEILLANCE
This presentation will cover the spectrum of genetic predisposition to cancer and the implications for risk stratification in populations and individuals. These data will then be applied to clinical translational applications to targeted cancer surveillance. For some common cancers such as breast cancer and colon cancer, rarer genetic germline variants associated with high risks of the relevant cancer are already determining the use of targeted intensive screening programmes. In other common cancers, such as prostate cancer, the application of genetic risk profiling is still in the research arena but uses standard methods of screening which would be applied to the general population if the risk/benefit ratio of screening were favourable. Finally, some cancer syndromes are still subject to more experimental methods of screening such as whole body MRI scanning in individuals with germline TP53 mutations (the SIGNIFY study). In summary, genetic variation is starting to be used to undertake targeted screening and the application of genetic profiling in populations and individuals to targeted screening will be discussed. Disclosure: Prof Eeles has received educational grants from Illumina, Tepnel (now GenProbe), Vista Diagnostics and Janssen Pharmaceuticals and honoraria from Succinct Communications.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].